Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 8-10 January 2013

Press release 11/01/2013

CVMP opinions on veterinary medicinal products

The Committee adopted by consensus a positive opinion for an extension of the existing authorisation for Loxicom (meloxicam) from Norbrook Laboratories Limited to add meloxicam 50-mg/g oral paste for horses.

The Committee adopted by consensus a positive opinion for a work-sharing type-II quality variation application for Rheumocam and Inflacam.

Renewals of marketing authorisations

The Committee adopted by consensus positive opinions for the renewals of the marketing authorisations for ProteqFlu and ProteqFlu-Te. The Committee, having re-assessed the benefit-risk balance of these products, concluded that their quality, safety and efficacy continue to be appropriately demonstrated and, therefore, recommended the renewals of the marketing authorisations.

Community referrals and related procedures

The Committee started a procedure to prepare a scientific opinion, under Article 30(3) of Regulation (EC) No 726/2004, regarding the substance lidocaine. The matter was submitted to the European Medicines Agency by the Netherlands, on the basis of new scientific data on metabolism, in order to address potential risks to the consumer resulting from the use of lidocaine in food-producing species.

Maximum residue limits

Further to requests and in accordance with CVMP guidance to include a substance in the list of substances considered as not falling within the scope of Regulation (EC) No 470/2009, the Committee concluded that the excipients PPG-2 myristyl ether propionate and polybutene do not fall within the scope of Regulation (EC) 470/2009.

Minor use minor species (MUMS) / limited markets

Following the Committee's review of one request for classification under the MUMS / limited-markets policy, which concerned a product with musculoskeletal indication for horses, the CVMP considered that the product was indicated for MUMS / limited market and was eligible for financial incentives.


The Committee reviewed the periodic safety update reports (PSURs) for Cimalgex, Emdocam, Gripovac 3, Ingelvac CircoFLEX, Loxicom, Proteq West Nile, Reconcile, RevitaCAM, Startvac, Zulvac 1 Bovis and Zuprevo and concluded that no further action or changes to their product literature were required.

Concept papers, guidelines and standard operating procedures


The Committee adopted a concept paper on genotoxic impurities (EMA/CVMP/SWP/398880/2012) for a three-month period of public consultation. The concept paper proposes the development of guidance outlining the data requirements and assessment approach needed for the determination of acceptable levels for impurities with genotoxic potential in veterinary medicinal products, taking account of both target animal safety and consumer safety.


The Committee adopted a concept paper on the development of a guideline on antimicrobial risk assessment (EMA/CVMP/680258/2012) for a three-month period of public consultation. The concept paper proposes the development of a guideline on antimicrobial-resistance risk assessment to be applied for all classes of antimicrobial agents. The guideline will provide a basis for transparent and consistent assessment of public-health risk related to antimicrobial resistance to be applied both by companies and regulatory bodies.

The documents above will be available on the Agency's website.

Working parties

The Committee elected Helen Jukes as chair of the newly established Antimicrobials Working Party for a three-year mandate.

International harmonisation

The Committee adopted a draft revised International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products (VICH) safety guideline for release in the European Union following sign-off by the VICH Steering Committee:

  • GL 23(R) on safety: Studies to evaluate the safety of residues of veterinary drugs in human food: Genotoxicity testing – three-month public consultation.

The guideline will be published on the Agency's website.

Related content

How useful was this page?

Add your rating